Sheashaa 2003.

Methods	RCT
Participants	Setting: Single centre Country: Egypt First, living related kidney transplant Mean age (± SD) Treatment group: 32.9 ± 9.9 Control group: 32.5 ± 10.8 Number (treatment/control): 100 (50/50) Sex (M/F) Treatment group: 44/6 Control group: 41/9
Interventions	Treatment group Basiliximab: 20 mg days 0 and 4 Control group Nothing Baseline immunosuppression CSA: 8 mg/kg/d adjusted to trough levels 200‐300 ng/mL (4 weeks) 125‐150 ng/mL (6 months) and 100‐125 ng/mL thereafter AZA: 1 mg/kg/d Steroids: 0.3 mg/kg/d at 1 month and 1.5 mg/kg/d at the 9th month
Outcomes	Mortality Graft loss Acute rejection Chronic allograft nephropathy Infection/CMV Malignancy
Notes	7 year follow‐up
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Stated "randomised", no further information provided
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Objective outcomes	Unclear risk	Not stated
Blinding (performance bias and detection bias) Subjective outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients followed up or accounted for
Selective reporting (reporting bias)	High risk	Primary outcomes for this review (death, graft loss and acute rejection) have been reported, however graft loss reported as percentages
Other bias	Unclear risk	Funding source not stated